These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 2854659)

  • 1. [Pentoxifylline and prostaglandins].
    Poggesi L; Boddi M; Scarti L; Masotti G
    Ric Clin Lab; 1988; 18 Suppl 2():37-46. PubMed ID: 2854659
    [No Abstract]   [Full Text] [Related]  

  • 2. Stimulatory effects of vascular prostaglandins on the antiaggregatory activities of pentoxifylline acetylsalicylic acid combinations in vitro.
    Weithmann KU; Just M; Schlotte V; Seiffge D
    Vasa; 1989; 18(4):273-6. PubMed ID: 2514520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced platelet aggregation by pentoxifylline stimulated prostacyclin release.
    Weithmann KU
    Vasa; 1981; 10(3):249-52. PubMed ID: 7025499
    [No Abstract]   [Full Text] [Related]  

  • 4. Some haemorheological factors in patients with arteriosclerosis obliterans after treatment of trental.
    Chyzy R; Lukjan H; Rość D; Bielawiec M; Sawicka J
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1987; 114(4):549-54. PubMed ID: 2446996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced platelet aggregation by effects of pentoxifylline on vascular prostacyclin isomerase and platelet cyclic AMP.
    Weithmann KU
    Gen Pharmacol; 1983; 14(1):161-2. PubMed ID: 6298055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical evaluation of the effects of pentoxifylline in patients with chronic peripheral circulatory disorders].
    Strano A; Davì G; Novo S; Avellone G; Pinto A
    Ric Clin Lab; 1981; 11 Suppl 1():303-11. PubMed ID: 7188117
    [No Abstract]   [Full Text] [Related]  

  • 7. The release of prostacyclin (PGI2) by pentoxifylline from human vascular tissue.
    Matzky R; Darius H; Schrör K
    Arzneimittelforschung; 1982; 32(10):1315-8. PubMed ID: 6817760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical pharmacology and pharmacokinetics of pentoxifylline].
    Mueller R
    Ric Clin Lab; 1988; 18 Suppl 2():3-33. PubMed ID: 3073514
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug stimulated prostacyclin release.
    Weithmann KU
    Ric Clin Lab; 1981; 11 Suppl 1():209-14. PubMed ID: 6324324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial results of pentoxifylline ('Trental') therapy in arteriosclerosis obliterans: possible mechanism of action.
    Kostka-Trabkowa E; Dembińska-Kieć A; Grodzińska L; Bieroń K; Gryglewski RJ
    Curr Med Res Opin; 1985; 9(6):407-15. PubMed ID: 3886306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a single pentoxifylline administration on platelet sensitivity, plasma factor activity, plasma-6-oxo-PGF1 alpha and thromboxane B2 in healthy volunteers.
    Pohanka E; Sinzinger H
    Prostaglandins Leukot Med; 1986 May; 22(2):191-200. PubMed ID: 3523540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet resistance to prostacyclin. Enhancement of the antiaggregatory effect of prostacyclin by pentoxifylline.
    Manrique RV; Manrique V
    Angiology; 1987 Feb; 38(2 Pt 1):101-8. PubMed ID: 3030162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of pentoxifylline on platelet aggregation.
    Nenci GG; Gresele P; Agnelli G; Ballatori E
    Pharmatherapeutica; 1981; 2(8):532-8. PubMed ID: 7255510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pentoxifylline treatment in patients with occlusive peripheral arterial disease. Circulatory changes and effects on prostaglandin synthesis.
    Poggesi L; Scarti L; Boddi M; Masotti G; Serneri GG
    Angiology; 1985 Sep; 36(9):628-37. PubMed ID: 3901827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of vascular diseases of the extremities using pentoxifylline].
    Di Perri T
    Ric Clin Lab; 1988; 18 Suppl 2():49-56. PubMed ID: 3073515
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of a single Ditazole dose on platelet aggregation and prostaglandin formation.
    Prisco D; Bartoletti A; Lombardi A
    Int J Clin Pharmacol Res; 1984; 4(2):129-36. PubMed ID: 6147319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of pentoxifylline and propentofylline on the turnover of polyphosphoinositides of the erythrocyte membrane and on the metabolism of arachidonic acid in platelets].
    Rossignol L; Plantavid M; Chap H; Douste-Blazy L
    Pathol Biol (Paris); 1988 Oct; 36(8 Pt 2):1073-5. PubMed ID: 2851765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on platelet aggregation with pentoxifylline: effect on neoplastic disorders and other new indications.
    Ambrus JL; Ambrus CM; Gastpar H
    J Med; 1979; 10(5):339-45. PubMed ID: 119023
    [No Abstract]   [Full Text] [Related]  

  • 19. Study of platelet aggregation in vivo. III. Effect of pentoxifylline.
    Gastpar H; Ambrus JL; Ambrus CM; Spavento P; Weber FJ; Thurber LE
    J Med; 1977; 8(3-4):191-7. PubMed ID: 407320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on platelet aggregation inhibitors in vivo. VIII. Effect of pentoxifylline on spontaneous tumor metastasis.
    Gordon S; Witul M; Cohen H; Sciandra J; Williams P; Gastpar H; Murphy GP; Ambrus JL
    J Med; 1979; 10(6):435-43. PubMed ID: 233697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.